IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: IL1RAP antibodies engineered to block IL1‐signaling and to enhance ADCC activity have shown strong therapeutic effects in patient‐derived chronic myeloid leukemia (CML) and AML xenograft models [53, 54].